文献速递生殖医学

促血管生成雌激素代谢物在正常卵泡发育及多囊卵巢综合征卵泡生长停滞中的意义

Significance of pro-angiogenic estrogen metabolites in normal follicular development and follicular growth arrest in polycystic ovary syndrome.
PubMed 文献 · Hum Reprod · 2020-01-01

本研究比较了有排卵的正常生育女性与无排卵多囊卵巢综合征(PCOS)女性不同大小卵泡的血清和卵泡液,发现PCOS患者卵泡液中促血管生成雌激素代谢物(4-OHE1、16-kE2、2-OHE2)和VEGF水平降低、AMH水平升高,外源性促性腺激素可提高PCOS患者促血管生成代谢物和VEGF水平至与对照相似。体外实验显示2-OHE2可增加PCOS患者颗粒细胞血管生成潜力和VEGF水平。

要点

  • PCOS无排卵患者卵泡液中促血管生成雌激素代谢物和VEGF低于正常生育女性
  • PCOS患者卵泡液AMH水平高于正常生育女性
  • 体外2-OHE2可提高PCOS颗粒细胞血管生成潜力和VEGF水平

核心结论

  • PCOS无排卵女性卵泡液促血管生成雌激素代谢物和VEGF水平降低,外源性促性腺激素可提高这些因子水平。
  • 促血管生成雌激素代谢物可能参与控制卵泡VEGF产生。

研究设计与样本

  • 比较实验研究,纳入正常生育女性20例、因卵泡停滞拟行卵巢打孔的PCOS女性17例、因男性因素不孕行IVF的对照女性12例和行IVF的PCOS女性17例。
  • 体外研究使用因男性因素不孕行IVF女性6例和行IVF的PCOS女性6例的颗粒黄体细胞,培养至6天。

主要发现

  • PCOS卵泡停滞患者窦卵泡(<10 mm)卵泡液中4-OHE1、16-kE2、2-OHE2和VEGF低于正常排卵生育女性(P < 0.05)。
  • PCOS卵泡停滞患者窦卵泡卵泡液AMH高于正常排卵生育女性(P < 0.05)。
  • IVF外源性促性腺激素使PCOS女性促血管生成雌激素代谢物和VEGF升高,与因男性因素不孕行IVF的对照女性接受促性腺激素后的水平相似。
  • 2-OHE2使PCOS女性颗粒细胞血管生成潜力和VEGF水平较基础条件升高(P < 0.05)。

局限性

  • 体外分析颗粒细胞可能不能反映2-OHE2促血管生成作用的体内机制,因为取卵时获得的颗粒细胞属于黄体早期,可能不能代表卵泡生长期间的颗粒细胞。
  • 因此,研究结果不能完全排除其他体内机制也参与PCOS血管生成缺陷的可能性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Do alterations in pro- and anti-angiogenic estrogen metabolites in follicular fluid (FF) contribute to the follicular growth arrest and anovulation associated with polycystic ovary syndrome (PCOS)? SUMMARY ANSWER: FF of PCOS women with anovulation have reduced levels of pro-angiogenic estrogen metabolites (EMs) and vascular endothelial growth factor (VEGF) compared to that of fertile women with regular menstrual cycles, but exogenous gonadotropins increase the pro-angiogenic EMs and VEGF levels in PCOS women. WHAT IS KNOWN ALREADY: PCOS is characterized by the arrest of follicular development that leads to chronic anovulation. Follicular arrest is generally associated with elevated plasma levels of luteinizing hormone (LH), androgens and anti-Mullerian hormone (AMH). There is also reduced angiogenesis in the follicles of PCOS women compared to those of normal cycling women. It is known that angiogenesis is a critical factor during follicular development. We and other investigators have explored the role of EMs in ovarian angiogenesis, particularly in human corpus luteum function, showing that 4-hydroxyestrone (4-OHE1) and 16-ketoestradiol (16-kE2) have pro-angiogenic effects while 2-methoxyestradiol (2-ME2) and 2-methoxyestrone (2-ME1) have anti-angiogenic effects. Additionally, 2-hydroxyestradiol (2-OHE2), which is produced in the ovary, has proliferative and pro-angiogenic properties. We hypothesized that EMs could be involved in angiogenesis necessary for ovarian follicular development in fertile women, and that dysregulation of these factors may contribute to follicular arrest in PCOS. The relationship between EMs, VEGF and AMH in the pathophysiology of follicular arrest in PCOS has not been previously studied at a follicular level in anovulatory women without ovulation induction. STUDY DESIGN, SIZE, DURATION: This is a comparative experimental study of serum and FF collected from different sized follicles (antral ˂10 mm and dominant ˃16 mm) of women with and without ovarian stimulation. The study included women with regular menstrual cycles who were proven to be fertile (n = 20) and PCOS women with follicular arrest who were candidates for ovarian drilling (n = 17), as well as other patients requiring ovarian stimulation, i.e. control women undergoing IVF for male factor infertility (n = 12) and PCOS women undergoing IVF (n = 17). In vitro studies were carried out on granulosa-lutein cells (GCs) obtained from subsets of women undergoing IVF for male factor infertility (n = 6) and PCOS women undergoing IVF (n = 6). GCs were maintained in culture for up to 6 days. PARTICIPANTS/MATERIALS, SETTING, METHODS: Intrafollicular estradiol, estrone and EMs concentrations were determined by high performance liquid chromatography-mass spectrometry. Testosterone in serum was measured by RIA, and LH, FSH and sex hormone-binding globulin in serum were measured with IRMA kits. AMH was determined in serum and FF by enzyme linked immunosorbant assay (ELISA). VEGF levels were measured in FF and conditioned medium by ELISA. Conditioned medium were obtained from cultured GCs. The angiogenic potential was assessed by in vitro angiogenic assays. MAIN RESULTS AND THE ROLE OF CHANCE: Pro-angiogenic EMs (4-OHE1, 16-kE2 and 2-OHE2) and VEGF were lower in FF of antral follicles of PCOS women with follicular arrest compared those of fertile women with ovulatory cycles (P < 0.05). In contrast, higher concentrations of AMH were found in FF of antral follicles from PCOS women with follicular arrest compared to those of fertile women with ovulatory cycles (P < 0.05). Exogenous gonadotropins used in IVF increased pro-angiogenic EMs and VEGF production in PCOS women, reaching similar profiles compared to control women receiving gonadotropins in their IVF treatment for male factor infertility. The pro-angiogenic EM 2-OHE2 increased the angiogenic potential and VEGF levels of GCs from PCOS women compared to the basal condition (P < 0.05). These findings suggest that there is a role for pro-angiogenic EMs in the control of follicular VEGF production. LIMITATIONS, REASONS FOR CAUTION: The limitations include the possibility that in vitro analysis of GCs might not reflect the in vivo mechanisms involved in the pro-angiogenic action of 2-OHE2 since GCs obtained at the time of oocyte retrieval belong to a very early stage of the luteal phase and might not be representative of GCs during follicular growth. Therefore, our findings do not conclusively rule out the possibility that other in vivo mechanisms also account for defective angiogenesis observed in PCOS. WIDER IMPLICATIONS OF THE FINDINGS: The present study highlights the significance of EMs, angiogenic factors and AMH and their interaction in the pathophysiology of follicular development in PCOS. This study provides new insights into the role of pro-angiogenic factors in follicular arrest in PCOS. STUDY FUNDING/COMPETING INTEREST(S): This study was funded by CONICYT/FONDECYT 1140693 and NIH grant R01HD083323. All authors declare no conflict of interest. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Henríquez S, Kohen P, Xu X, et al. Significance of pro-angiogenic estrogen metabolites in normal follicular development and follicular growth arrest in polycystic ovary syndrome. Hum Reprod. 2020. PMID: 32558920. doi:10.1093/humrep/deaa098

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。